Abstract:Background: CEP290-associated inherited retinal degeneration causes severe early-onset vision loss due to pathogenic variants in CEP290. EDIT-101 is a clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) gene-editing complex designed to treat inherited retinal degeneration caused by a specific damaging variant in intron 26 of CEP290 (IVS26 variant). Methods: We performed a phase 1-2, open-label, single-ascending-dose study in which persons 3 years of age or older with CEP290-associated inherited retinal degeneration caused by a homozygous or compound heterozygous IVS26 variant received a subretinal injection of EDIT-101 in the worse (study) eye. The primary outcome was safety, which included adverse events and dose-limiting toxic effects. Key secondary efficacy outcomes were the change from baseline in the best corrected visual acuity, the retinal sensitivity detected with the use of full-field stimulus testing (FST), the score on the Ora-Visual Navigation Challenge mobility test, and the vision-related quality-of-life score on the National Eye Institute Visual Function Questionnaire-25 (in adults) or the Children's Visual Function Questionnaire (in children). Results: EDIT-101 was injected in 12 adults 17 to 63 years of age (median, 37 years) at a low dose (in 2 participants), an intermediate dose (in 5), or a high dose (in 5) and in 2 children 9 and 14 years of age at the intermediate dose. At baseline, the median best corrected visual acuity in the study eye was 2.4 log10 of the minimum angle of resolution (range, 3.9 to 0.6). No serious adverse events related to the treatment or procedure and no dose-limiting toxic effects were recorded. Six participants had a meaningful improvement from baseline in cone-mediated vision as assessed with the use of FST, of whom 5 had improvement in at least one other key secondary outcome. Nine participants (64%) had a meaningful improvement from baseline in the best corrected visual acuity, the sensitivity to red light as measured with FST, or the score on the mobility test. Six participants had a meaningful improvement from baseline in the vision-related quality-of-life score. Conclusions: The safety profile and improvements in photoreceptor function after EDIT-101 treatment in this small phase 1-2 study support further research of in vivo CRISPR-Cas9 gene editing to treat inherited retinal degenerations due to the IVS26 variant of CEP290 and other genetic causes. (Funded by Editas Medicine and others; BRILLIANCE ClinicalTrials.gov number, NCT03872479.).

CEP290 gene transfer rescues Leber congenital amaurosis cellular phenotype

LEBER CONGENITAL AMAUROSIS DUE TO CEP290 MUTATIONS-SEVERE VISION IMPAIRMENT WITH A HIGH UNMET MEDICAL NEED: A Review

Reprogramming of Ipscs to NPCEC-like Cells by Biomimetic Scaffolds for Zonular Fiber Reconstruction

A Novel CEP290 Disease-Causing Variant Identified in a Patient with Leber Congenital Amaurosis Using a Medical Diagnostic Panel Sequencing.

Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10

Gene Therapy of Dominant CRX-Leber Congenital Amaurosis using Patient Stem Cell-Derived Retinal Organoids

Unlocking therapeutic potential: dual gene therapy for ameliorating the disease phenotypes in a mouse model of RPE65 Leber congenital amaurosis

Effective AAV-mediated gene replacement therapy in retinal organoids modelling AIPL1-associated LCA4

Eupatilin improves cilia defects in human CEP290 ciliopathy models

Central visual pathways affected by degenerative retinal disease before and after gene therapy

Gene Therapy Rescues Cone Structure and Function in the 3-Month-oldrd12mouse: A Model for Midcourse RPE65 Leber Congenital Amaurosis

Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis

GUCY2D Gene Loss-of-Function Mutations Responsible for Leber Congenital Amaurosis 1

Clinical and genetic studies for a cohort of patients with Leber congenital amaurosis

The Clinical Findings, Pathogenic Variants, and Gene Therapy Qualifications Found in a Leber Congenital Amaurosis Phenotypic Spectrum Patient Cohort

Differential Proteomics And Functional Research Following Gene Therapy In A Mouse Model Of Leber Congenital Amaurosis

Generation and Characterization of Induced Pluripotent Stem Cells and Retinal Organoids from a Leber's Congenital Amaurosis Patient with Novel RPE65 Mutations.

Gene augmentation therapy to rescue degenerative photoreceptors in a Cwc27 mutant mouse model

Gene Editing for CEP290-Associated Retinal Degeneration

Efficacy of Intravitreal Multi-Characteristic Opsin (MCO-010) Optogenetic Gene Therapy in a Mouse Model of Leber Congenital Amaurosis